-Reuters
What’s Going On With Chemomab Therapeutics Stock Today
Chemomab Therapeutics Ltd (NASDAQ: CMMB) reported topline results from secondary Phase 2a liver fibrosis trial analyses assessing CM-101 in patients with
Related Posts
Sow Good Q1 EPS $0.06 Up From $(0.29) YoY; Revenue $11.41M Up From $198,930 YoY
First Quarter 2024 Highlights vs. Same Year-Ago QuarterRevenue in the first quarter of 2024 increased significantly to $11.4 million compared to approximately $198.9K for the same period in 2023. The increase was driven
Deutsche Bank Maintains Buy on Verisk Analytics, Lowers Price Target to $195
Deutsche Bank analyst Faiza Alwy maintains Verisk Analytics (NASDAQ:VRSK) with a Buy and lowers the price target from $227 to $195.
Ethereum’s Long-Awaited Dencun Upgrade Sets Final Timeline For Deployment
The Ethereum Foundation announced the final timeline for its much-anticipated Dencun network upgrade, marking a significant milestone in Ethereum's continuous evolution.